Johnson & Johnson

Johnson & Johnson· Health · 7 sources · Sep 21, 2026Story

J&J's Caplyta meets main goal in bipolar mania phase 3 trial

J&J’s Caplyta cut manic symptoms 4.8 YMRS points more than placebo at Week 3 in Phase 3 Study 451; not yet approved for bipolar mania.

Health· Sep 21, 2026

+2

Johnson & Johnson· Business · 8 sources · Sep 11, 2026Story

Apollo Eyes $20 Billion J&J Orthopedics Unit

Apollo Global Management is poised to acquire Johnson & Johnson's DePuy Synthes orthopedics unit for about $20 billion, a deal that would value the asset at roughly two times its sales as J&J considers a tax-free spin-off or other paths to sharpen focus on higher-growth healthcare areas. DePuy Synthes generated about $9.3 billion in 2025 revenue but trails faster-growing segments and carries thousands of hip-implant lawsuits that would influence buyer pricing.

Business· Sep 11, 2026

0

Johnson & Johnson· Business · 8 sources · Jul 22, 2026Story

J&J Wins FDA De Novo OTTAVA System

Johnson & Johnson has received FDA De Novo clearance for its Ottava robotic surgical system, marking its entry into the U.S. market as a table-integrated, space-saving alternative aimed at general soft-tissue procedures. The company plans a selective U.S. rollout and ongoing global expansion, supported by an inguinal hernia trial and continued development of additional indications and regulatory approvals amid competition from Intuitive Surgical's established da Vinci platform.

Business· Jul 22, 2026

0

Johnson & Johnson· Reporting · 1 source · Aug 27, 2024Story

Johnson & Johnson Acquires V-Wave For $1.7 Billion To Boost Heart Failure Treatment Portfolio‌ ‌

Global healthcare giant Johnson & Johnson (J&J) announced on Tuesday that it will acquire Israeli startup V-Wave for up to $1.7 billion, in a strategic move by J&J to bolster its position in the fast-growing congestive…

Reporting· Aug 27, 2024

0

Johnson & Johnson

Johnson & Johnson

J&J's Caplyta meets main goal in bipolar mania phase 3 trial

Apollo Eyes $20 Billion J&J Orthopedics Unit

J&J Wins FDA De Novo OTTAVA System

Johnson & Johnson Acquires V-Wave For $1.7 Billion To Boost Heart Failure Treatment Portfolio‌ ‌

Johnson & Johnson across IJR

Miembros destacados

Johnson & Johnson across IJR

Últimas noticias y debate sobre Johnson & Johnson

J&J's Caplyta meets main goal in bipolar mania phase 3 trial

Apollo Eyes $20 Billion J&J Orthopedics Unit

J&J Wins FDA De Novo OTTAVA System

Johnson & Johnson Acquires V-Wave For $1.7 Billion To Boost Heart Failure Treatment Portfolio‌ ‌

Johnson & Johnson across IJR

Miembros destacados

Johnson & Johnson across IJR